These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 5643297)

  • 21. Protective effect of zinc on cyclophosphamide-induced hematoxicity and urotoxicity.
    Ayhanci A; Uyar R; Aral E; Kabadere S; Appak S
    Biol Trace Elem Res; 2008; 126(1-3):186-93. PubMed ID: 18641924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Random prospective study cyclophosphamide, doxorubicin, and methotrexate (CAM) combination chemotherapy versus single-agent sequential chemotherapy in non small cell lung cancer.
    Einhorn LH; Williams SD; Stevens EE; Bond WH; Chenoweth L
    Cancer Treat Rep; 1982 Dec; 66(12):2005-11. PubMed ID: 6291763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies on the correlation between rate of biotransformation and haematological toxicity of cyclophosphamide.
    Mouridsen HT; Witten J; Frederiksen PL; Hulsbaek I
    Acta Pharmacol Toxicol (Copenh); 1978 Oct; 43(4):328-30. PubMed ID: 716950
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
    Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
    Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Polychemotherapy of small-cell lung cancer].
    Krawczyk K; Krochmal M; Pawlicki M; Kulpa J
    Pneumonol Pol; 1983 Feb; 51(2):101-5. PubMed ID: 6308583
    [No Abstract]   [Full Text] [Related]  

  • 26. Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers.
    Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK
    Cancer Treat Rep; 1981; 65(5-6):453-8. PubMed ID: 6263477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of VP-16-213, cyclophosphamide, doxorubicin, and cisplatin (V-CAP) in advanced large cell lung cancer.
    Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK; Coles DT
    Cancer Treat Rep; 1981; 65(7-8):715-7. PubMed ID: 6166376
    [No Abstract]   [Full Text] [Related]  

  • 28. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
    Shiraga E; Barichello JM; Ishida T; Kiwada H
    Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Shock doses of endoxan in the therapy of malignant lung neoplasms (based on personal observations)].
    Ratajek M
    Wiad Lek; 1970 Jan; 23(1):15-8. PubMed ID: 5412426
    [No Abstract]   [Full Text] [Related]  

  • 30. [Importance of the initial chemotherapy dose in the treatment of small cell lung carcinoma: therapeutic perspectives].
    Le Chevalier T; Le Cesne A; Arriagada R
    Bull Cancer; 1995; 82 Suppl 1():24s-28s. PubMed ID: 7626850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential combination of vincristine, adriamycin and cyclophosphamide (VAC), and radiotherapy in advanced non-small-cell lung cancer.
    Wils JA; Ribot JG
    Neth J Med; 1982; 25(2):43-6. PubMed ID: 7070560
    [No Abstract]   [Full Text] [Related]  

  • 32. [Studies on the administration of massive doses of endoxan in pulmonary neoplasms].
    Górecki R; Brodziak R; Gondorowicz K; Stanek S
    Gruzlica; 1969 Mar; 37(3):251-4. PubMed ID: 4182112
    [No Abstract]   [Full Text] [Related]  

  • 33. Prospective evaluation of rotating chemotherapy in advanced breast cancer. An Eastern Cooperative Oncology Group Trial.
    Tormey D; Gelman R; Falkson G
    Am J Clin Oncol; 1983 Feb; 6(1):1-18. PubMed ID: 6340458
    [No Abstract]   [Full Text] [Related]  

  • 34. Lymphomatoid granulomatosis with long survival.
    Al-Arfaj AS
    Saudi Med J; 2001 Jun; 22(6):541-3. PubMed ID: 11426249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The quality of life after chemotherapy in advanced non-small cell lung cancer patients].
    Słowik-Gabryelska A; Szczepanik A; Kalicka A
    Pol Merkur Lekarski; 1999 Jan; 6(31):18-22. PubMed ID: 10344148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EST 0469B--comparison of high- and low-dose cyclophosphamide in human lung cancer.
    Hall TC; Pocock S; Brodovsky H; Horton J; Shnider BI; Colsky J; Oberfield RA
    Med Pediatr Oncol; 1978; 5(1):231-40. PubMed ID: 370535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Adriamycin in the combined chemotherapy of small-cell lung cancer].
    Perevodchikova NI; Bychkov MB; Ausekar BV
    Antibiotiki; 1983 Aug; 28(8):628-32. PubMed ID: 6314882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequential high dose-density chemotherapy with two active regimens for advanced small cell lung cancer.
    Vigani A; Pensa F; Vaira F; Bancalari L; Cordani S; Maggiani R; Canessa P; Pronzato P
    Anticancer Res; 2000; 20(5C):4015-8. PubMed ID: 11268494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of endoxan on changes of cellular elements in peripheral blood].
    Sadliński C; Stadnik J; Wodarczyk D; Biskupek H
    Pol Tyg Lek; 1969 Oct; 24(47):1811-3. PubMed ID: 5363089
    [No Abstract]   [Full Text] [Related]  

  • 40. Combination chemotherapy in squamous cell carcinoma of the lung.
    Krzakowski MJ; Swierz J
    Chemioterapia; 1984 Apr; 3(2):75-8. PubMed ID: 6085285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.